Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib

Lay Summary The real-world incidence of JAK inhibitor-associated acne (JAKne) in patients with inflammatory bowel disease is significantly higher than reported in clinical trials. Younger age, female sex, and higher dosage have been identified as potential risk factors.